KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The company has improved access to quality healthcare for seniors across both urban and rural areas
This acquisition expands HGM's healthcare platform capabilities in revenue cycle management
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Subscribe To Our Newsletter & Stay Updated
